Breaking News
December 10, 2018 - Risk Analysis publishes special issue on communicating about Zika virus
December 10, 2018 - Botox May Help Prevent Post-Op A-Fib
December 10, 2018 - African-American mothers rate boys higher for ADHD
December 10, 2018 - Graphic warning labels cancel out cigarettes’ appeal to young people
December 10, 2018 - Australian researchers to study gas inhalational anaesthetic and likelihood of cancer return
December 10, 2018 - Individual neurons located within the brain have implications for psychiatric diseases
December 10, 2018 - Researchers improve bariatric surgery scoring system to extend prediction time for diabetic remission
December 10, 2018 - Combo therapy not needed if low RA disease activity achieved
December 10, 2018 - Novel therapeutic targets based on biology of aging show promise for Alzheimer’s disease
December 10, 2018 - UC San Diego professor receives NCI Outstanding Investigator Award for cancer research
December 10, 2018 - Study evaluates placental mesenchymal stem cell sheets for myocardial repair and regeneration
December 10, 2018 - Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
December 10, 2018 - Study clarifies ApoE4’s role in dementia
December 10, 2018 - Eating disorders now a top priority with Australian Government
December 10, 2018 - Neuronal activity in the brain allows prediction of risky or safe decisions
December 10, 2018 - FDA Alerts Health Care Professionals and Patients Not to Use Drug Products Intended to be Sterile from Promise Pharmacy
December 10, 2018 - Improving dementia care and treatment saves thousands of pounds in care homes
December 10, 2018 - Heroin-assisted treatment can offer benefits, reduce harms
December 10, 2018 - People covered by Michigan’s expanded Medicaid program report improvements in health, finds study
December 10, 2018 - Hazelnuts improve micronutrient levels in older adults
December 9, 2018 - History of Partner Violence Tied to Menopause Symptoms
December 9, 2018 - Clean Up Safely After a Disaster|Natural Disasters and Severe Weather
December 9, 2018 - Drug wholesalers drove fentanyl’s deadly rise, report concludes
December 9, 2018 - Deprescribing could help manage polypharmacy in older adults
December 9, 2018 - Retraction of article “Joy of cooking too much” from journal
December 9, 2018 - FDA Warns of Rare Stroke Risk With MS Drug Lemtrada (Alemtuzumab)
December 9, 2018 - Feds say heroin, fentanyl remain biggest drug threat to US
December 9, 2018 - Eliminating microglia can reverse some aspects of stress sensitization, study shows
December 9, 2018 - New genetic insight could help treat rare debilitating heart and lung condition
December 9, 2018 - MiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 9, 2018 - Work with your doctor to weigh pros, cons of treatment options for hyperthyroidism
December 9, 2018 - CWRU researcher secures $14.6 million funding for genetic study into Alzheimer’s disease
December 9, 2018 - High intensity statin treatment and adherence could save more lives
December 9, 2018 - Surgery patients use only 1/4 of prescribed opioids, and prescription size matters
December 9, 2018 - AXT offers Phi Optics upgrade to QPI systems for inverted light microscopes
December 9, 2018 - New booklet could help improve conditions of young pupils with albinism
December 9, 2018 - Few Physicians Work in Practices That Use Telemedicine
December 9, 2018 - Older Adults and Oral Health
December 9, 2018 - Health utility values improve after septorhinoplasty
December 9, 2018 - New EU-funded project provides insight into how the brain develops
December 9, 2018 - Expanded use of tele-emergency services can help strengthen rural hospitals
December 9, 2018 - Infections in the Young May Be Tied to Risk for Mental Illness: Study
December 9, 2018 - Profile: Native Hawaiians and Pacific Islanders
December 9, 2018 - Snoring poses greater cardiac risk to women
December 9, 2018 - Researcher takes further steps in understanding how and why cute aggression occurs
December 9, 2018 - Researchers create new light-activated tools for controlling neurons
December 9, 2018 - Spinal cord injury disrupts the body’s internal clock, study shows
December 9, 2018 - Babies recognize nested structures similar to our grammar
December 9, 2018 - UT Austin researcher receives $2.5 million CZI grant for neurodegenerative disease research
December 9, 2018 - Sleep problems found to be prevalent and increasing among college students
December 9, 2018 - Study reveals why some children are susceptible to the effects of maltreatment
December 9, 2018 - Study investigates influence of different opioids on driving performance
December 9, 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
December 9, 2018 - Eliminating microglia prevents heightened immune sensitivity after stress
December 9, 2018 - Boys with social difficulties are at greatest risk of early substance use
December 9, 2018 - ‘Wrong’ connective tissue cells linked to worse prognosis in breast cancer patients
December 8, 2018 - Chronic, refractory schizophrenia patients benefit from targeted cognitive training
December 8, 2018 - Advertising in kids’ apps more prevalent than parents may realize
December 8, 2018 - New way to trace the transmission histories of rare genetic diseases
December 8, 2018 - ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
December 8, 2018 - Results of pediatric genomic epilepsy tests often reclassified
December 8, 2018 - New way of controlling HIV latency to completely eradicate the virus
December 8, 2018 - Phasefocus to showcase the Livecyte 2 at ASCB
December 8, 2018 - KHN’s ‘What the Health?’ Is health spending the next big political issue?
December 8, 2018 - Mussels take in microplastic pollution fibers and flush most of them out again
December 8, 2018 - AHA: How to Stop Smoking … for Good
December 8, 2018 - Scientists overturn odds to make Parkinson’s discovery
December 8, 2018 - Health benefits of producing marula vinegar
December 8, 2018 - Failure of critical cellular energy sensor responsible for CKD progression, study finds
December 8, 2018 - Ethnicity can be reliable indicator of gut microbiota diversity
December 8, 2018 - Safe Sleep for Baby | NIH News in Health
December 8, 2018 - Study looks at ways technology can support nutritional needs of Parkinson’s patients
December 8, 2018 - Infant milk allergy is being overdiagnosed say experts
December 8, 2018 - Graphene may one day be used to test for ALS
December 8, 2018 - Houston Methodist launches real-time website to track flu cases
December 8, 2018 - RedHill Announces Positive Top-Line Results from Confirmatory Phase 3 Study with Talicia for H. pylori Infection
December 8, 2018 - A way to measure obesity and health beyond BMI
December 8, 2018 - New diagnostic tools may help identify breast cancer patients who could benefit from targeted therapies
December 8, 2018 - Duke-NUS researchers highlight possible role of bioaerosol sampling in pandemic surveillance
December 8, 2018 - Study quantifies links between alcohol, drug use and violent deaths
A Role for Budesonide in Autoimmune Hepatitis?

A Role for Budesonide in Autoimmune Hepatitis?

image_pdfDownload PDFimage_print

Action Points

  • Note that this observational study of budesonide in autoimmune hepatitis suggests that the agent, which undergoes extensive first-pass metabolism, may be effective when more systemic steroids are not tolerated.
  • At baseline, the mean budesonide dose was 9 mg per day.

Budesonide may be an acceptable second-line treatment for autoimmune hepatitis among patients who experience steroid-induced side effects or who are dependent on high doses of prednisolone, a retrospective single-center analysis suggested.

Among 60 patients who were switched to budesonide from prednisolone, 55% were considered responders after 6 months of treatment, as were 70% after 12 months, according to Christoph Schramm, MD, and colleagues from University Medical Center Hamburg-Eppendorf in Germany.

In addition, the rates of biochemical response — defined as normalization of serum levels of aminotransferases and IgG — were 68% after 24 months and 70% after 36 months, the researchers reported in Clinical Gastroenterology and Hepatology.

Autoimmune hepatitis is characterized by liver inflammation, high levels of aminotransferases and IgG, and the presence of circulating autoantibodies such as antinuclear antibodies (ANA) and smooth muscle antibodies (SMA). Standard treatment involves corticosteroids alone or with azathioprine.

Prednisolone typically has been favored because of its efficacy in controlling liver inflammation, but an estimated 44% of patients develop steroid-associated side effects with this agent, and up to 15% are refractory and require alternative treatments.

Budesonide is a synthetic steroid derived from 16α-hydroxyprednisolone that has fewer adverse effects than prednisolone because its hepatic first-pass clearance exceeds 90%. This drug is not recommended for patients with cirrhosis because of adverse events associated with portosystemic shunting.

Previous studies evaluating budesonide in autoimmune hepatitis have had conflicting results, with one randomized trial showing efficacy for both remission and maintenance after 6 and 12 months but another showing low rates of response at 6 months. Moreover, longer-term data are sparse, and autoimmune hepatitis often requires lifelong therapy.

Therefore, to explore a possible role for budesonide among patients with inadequate responses or intolerance to prednisolone, Schramm and colleagues retrospectively analyzed data that had been collected prospectively at their center from 2001 to 2016.

Among 328 patients with autoimmune hepatitis in their database, 60 (51 women) had been switched to budesonide from prednisolone — 30 because of side effects and 30 because of the inability to taper the steroid dose sufficiently. The mean age at the time of diagnosis was 42, and most patients were positive for both ANA and SMA.

Concomitant autoimmune diseases were present in some patients, such as thyroid disease in 12%, diabetes in 7%, rheumatoid arthritis in 3%, and lupus in 2%.

The mean duration of prednisolone therapy before switching was 47 months, and the mean daily dose was 8.5 mg.

In 10 patients, budesonide was given as monotherapy, while 40 also received azathioprine, six were given mycophenolate mofetil (CellCept), and two received 6-mercaptopurine.

Mean alanine aminotransferase levels were 123 U/L at the beginning of budesonide treatment, declining to 45.7 U/L at 6 months (P<0.001) and thereafter remaining stable through 36 months, when the mean level was 50.3 U/L.

The mean serum IgG levels also declined, from 14.2 g/L at budesonide initiation to 12.2 g/L at 6 months (P=0.006), and were 12.8 g/L at 36 months.

The mean dose of budesonide was 9 mg/day at baseline, and the mean maintenance dosage was 6.2 mg/day.

Among patients who had switched to budesonide because of adverse effects with prednisolone, responses at 6, 12, 24, and 36 months were seen in 50%, 65%, 70%, and 72% of patients, respectively.

Among those who switched because of the inability to taper prednisolone, responses at those time points were seen in 60%, 75%, 64%, and 69%, respectively. The mean dosages were 5.8 mg after 6 months and 5.1 mg/day after 36 months, “showing efficacy of medium doses of budesonide in the group of patients with prior prednisolone dependency,” the authors noted.

A total of 17 patients switched back to prednisolone after a mean of 17.1 months, because of side effects or lack of efficacy. In nine of these, there was a flare of aminotransferase levels, three developed cirrhosis, and one had new onset bullous pemphigoid.

Among 15 patients who had osteopenia during prednisolone treatment, six had improved T-scores and eight remained stable during budesonide therapy, while only one had T-score worsening.

The lack of bone mineral density deterioration during budesonide treatment supports the use of this treatment approach among patients who did not respond to prednisolone, the authors suggested. “However, treatment efficacy and tolerance must be monitored because efficacy of budesonide may not suffice to maintain remission or control concomitant autoimmune disease and budesonide-induced side effects may occur in patients even in the absence of cirrhosis.”

In an accompanying editorial, Michael P. Manns, MD, of Hannover Medical School in Germany, and two colleagues said there is a need for additional treatments for autoimmune hepatitis that utilize different mechanisms of action, such as calcineurin inhibitors and monoclonal antibodies including rituximab (Rituxan) and infliximab (Remicade).

“It is hoped that ongoing initiatives will lead to a consensus approach for the development of effective second-line therapies for this difficult-to-treat group of patients,” the editorialists stated.

The limitations of the study, Schramm and colleagues wrote, included the retrospective design and the single tertiary care setting.

The study was supported by the YAEL Foundation, the German Research Foundation, and the Helmut and Hannelore Greve Foundation.

The Schramm and c0-authors reported financial relationships with the Falk Foundation and Falk Pharma.

The editorialists reported financial relationships with Novartis, Basel, the Falk Foundation, and the Falk Pharma.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles